Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the cash-burn details behind Ovaprene® trials or spotting when Dare Bioscience insiders buy shares can take hours across multiple SEC PDFs. Biotech disclosures are dense, and Dare’s focus on women’s health brings extra layers of clinical data that investors cannot afford to miss. That complexity is the problem we solve.
Stock Titan’s AI reads every new submission the moment it hits EDGAR, then delivers plain-English answers. Need the Dare Bioscience quarterly earnings report 10-Q filing? Our summary highlights R&D spend, grant income and runway in seconds. Curious about Dare Bioscience insider trading Form 4 transactions? Real-time alerts flag each Dare Bioscience Form 4 insider transactions real-time, showing option grants tied to FDA milestones. For sudden study updates, the platform turns any Dare Bioscience 8-K material events explained into a concise brief you can read before the market reacts.
Every filing type is covered:
- 10-K – The Dare Bioscience annual report 10-K simplified spotlights pipeline status, partnership revenue and risk factors.
- 10-Q – Quarterly burn-rate trends with AI charts for quick Dare Bioscience earnings report filing analysis.
- 8-K – Trial results, FDA feedback, licensing deals distilled so you can act fast.
- Form 4 – Track Dare Bioscience executive stock transactions Form 4 to gauge insider confidence.
- DEF 14A – The Dare Bioscience proxy statement executive compensation section decodes pay structures vs. milestones.
Whether you’re a portfolio manager comparing cash runway or an analyst understanding Dare Bioscience SEC documents with AI, our platform ensures Dare Bioscience SEC filings explained simply are always one click away—complete, current and clear.
Law Custodial Inc. filed a Schedule 13G reporting beneficial ownership of 1,409,167 ordinary shares of Dare Bioscience, Inc., representing approximately
MarDee Haring-Layton, identified as an officer (Chief Accounting Officer) and director of Dare Bioscience, Inc. (DARE), was granted an employee stock option for 57,000 shares on 09/04/2025 at an exercise price of $2.13. The Form 4 reports the options as beneficially owned directly following the grant, totaling 57,000 shares. The explanatory note states the option is a retention award that vests and becomes exercisable on 09/04/2027, unless certain performance criteria are met earlier, and the table indicates an expiration date of 09/04/2035. The Form is signed by the reporting person on 09/04/2025.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
